In addition, a preclinical study showed that Mer590, which is a monoclonal antibody, inhibits the MERTK-mediated signaling pathway, reduces colony formation, and sensitizes NSCLC cells to chemotherapy [95]. This evidence concerns the gene MERTK and non-small cell lung carcinoma.